SELLAS Life Sciences Group, Inc. (FRA:RXK3)

Germany flag Germany · Delayed Price · Currency is EUR
3.535
+0.030 (0.86%)
Last updated: Jan 20, 2026, 7:54 PM CET
246.57%
Market Cap540.34M +714.4%
Revenue (ttm)n/a
Net Income-22.11M
EPS-0.24
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume450
Average Volume1,677
Open3.370
Previous Close3.505
Day's Range3.250 - 3.535
52-Week Range0.883 - 4.495
Betan/a
RSI50.41
Earnings DateMar 18, 2026

About FRA:RXK3

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Angelos Stergiou
Employees 15
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RXK3
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements